Bruker (BRKR) Stock Forecast, Price Target & Predictions
BRKR Stock Forecast
Bruker stock forecast is as follows: an average price target of $79.00 (represents a 38.60% upside from BRKR’s last price of $57.00) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
BRKR Price Target
The average price target for Bruker (BRKR) is $79.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $80.00 to $78.00. This represents a potential 38.60% upside from BRKR's last price of $57.00.
BRKR Analyst Ratings
According to 8 Wall Street analysts, Bruker's rating consensus is 'Buy'. The analyst rating breakdown for BRKR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 1 'Hold' (12.50%), 1 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).
Bruker Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Patrick Donnelly | Citigroup | $80.00 | $67.54 | 18.45% | 40.35% |
| Aug 27, 2024 | Brandon Couillard | Wells Fargo | $78.00 | $63.95 | 21.97% | 36.84% |
| May 20, 2024 | Daniel Arias | Stifel Nicolaus | $77.00 | $76.47 | 0.69% | 35.09% |
| May 05, 2021 | Tycho Peterson | J.P. Morgan | $60.00 | $68.86 | -12.87% | 5.26% |
The latest Bruker stock forecast, released on Sep 23, 2024 by Patrick Donnelly from Citigroup, set a price target of $80.00, which represents a 18.45% increase from the stock price at the time of the forecast ($67.54), and a 40.35% increase from BRKR last price ($57.00).
Bruker Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $80.00 | $78.33 |
| Last Closing Price | $57.00 | $57.00 | $57.00 |
| Upside/Downside | -100.00% | 40.35% | 37.42% |
In the current month, the average price target of Bruker stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bruker's last price of $57.00. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 05, 2024 | Goldman Sachs | Sell | Upgrade | |
| Oct 15, 2024 | Barclays | Overweight | Initialise | |
| Sep 30, 2024 | Wolfe Research | Peer Perform | Downgrade | |
| Sep 23, 2024 | Citigroup | Buy | Buy | Hold |
| Aug 28, 2024 | Wells Fargo | Overweight | Positive | Initialise |
| Aug 27, 2024 | Wells Fargo | Overweight | Initialise | |
| Aug 07, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Jul 10, 2024 | Citigroup | Buy | Buy | Hold |
| May 20, 2024 | Citigroup | Buy | Buy | Hold |
| May 20, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Feb 15, 2024 | UBS | Buy | Buy | Hold |
| Feb 14, 2024 | Needham | Overweight | Upgrade | |
| Aug 22, 2022 | Citigroup | Buy | Upgrade |
Bruker's last stock rating was published by Goldman Sachs on Dec 05, 2024. The company Upgrade its BRKR rating from "null" to "Sell".
Bruker Financial Forecast
Bruker Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $854.50M | $742.80M | $681.90M | $685.30M | $708.40M | $638.90M | $588.40M | $595.00M | $683.50M | $608.90M | $570.80M | $554.70M | $627.50M | $511.40M | $424.60M | $424.00M | $599.90M | $521.10M |
| Avg Forecast | $1.08B | $955.71M | $906.64M | $865.08M | $1.01B | $907.82M | $855.99M | $820.37M | $962.38M | $866.46M | $799.47M | $729.88M | $807.45M | $714.61M | $647.82M | $639.76M | $680.10M | $609.98M | $588.22M | $572.58M | $661.93M | $575.19M | $537.10M | $513.06M | $603.36M | $484.92M | $391.49M | $443.92M | $576.91M | $494.16M |
| High Forecast | $1.10B | $974.62M | $924.57M | $882.19M | $1.03B | $925.78M | $872.92M | $832.94M | $963.64M | $867.09M | $799.47M | $744.32M | $807.66M | $727.78M | $660.64M | $652.42M | $693.56M | $609.98M | $588.22M | $572.58M | $661.93M | $575.19M | $537.10M | $513.06M | $603.36M | $484.92M | $391.49M | $443.92M | $576.91M | $494.16M |
| Low Forecast | $1.06B | $939.92M | $891.65M | $850.78M | $996.36M | $892.81M | $841.84M | $810.21M | $961.15M | $865.83M | $799.47M | $717.81M | $807.22M | $703.69M | $637.12M | $629.19M | $668.86M | $609.98M | $588.22M | $572.58M | $661.93M | $575.19M | $537.10M | $513.06M | $603.36M | $484.92M | $391.49M | $443.92M | $576.91M | $494.16M |
| # Analysts | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 6 | 8 | 4 | 1 | 1 | 2 | 8 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.05% | 1.07% | 1.04% | 1.05% | 1.00% | 1.04% | 1.03% | 1.06% | 1.06% | 1.08% | 1.04% | 1.05% | 1.08% | 0.96% | 1.04% | 1.05% |
Bruker's average Quarter revenue forecast for Mar 24 based on 1 analysts is $729.88M, with a low forecast of $717.81M, and a high forecast of $744.32M. BRKR's average Quarter revenue forecast represents a -14.58% decrease compared to the company's last Quarter revenue of $854.50M (Dec 23).
Bruker EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 6 | 8 | 4 | 1 | 1 | 2 | 8 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $144.90M | $160.50M | $117.50M | $153.10M | $161.40M | $155.30M | $108.00M | $125.70M | $143.90M | $137.20M | $114.60M | $115.80M | $147.40M | $104.80M | $56.80M | $36.00M | $136.90M | $99.60M |
| Avg Forecast | $208.24M | $184.99M | $175.49M | $167.45M | $196.10M | $175.72M | $165.69M | $158.80M | $186.28M | $167.72M | $154.75M | $130.69M | $156.29M | $138.32M | $125.40M | $118.80M | $162.91M | $121.43M | $117.10M | $93.92M | $131.77M | $114.50M | $106.92M | $66.56M | $120.11M | $96.53M | $77.93M | $47.72M | $114.84M | $98.37M |
| High Forecast | $212.36M | $188.65M | $178.96M | $170.76M | $199.98M | $179.20M | $168.97M | $161.23M | $186.53M | $167.84M | $154.75M | $156.82M | $156.33M | $140.87M | $127.88M | $142.57M | $195.49M | $121.43M | $117.10M | $112.70M | $131.77M | $114.50M | $106.92M | $79.88M | $120.11M | $96.53M | $77.93M | $57.27M | $114.84M | $98.37M |
| Low Forecast | $204.80M | $181.93M | $172.59M | $164.68M | $192.86M | $172.82M | $162.95M | $156.83M | $186.05M | $167.59M | $154.75M | $104.55M | $156.25M | $136.21M | $123.32M | $95.04M | $130.33M | $121.43M | $117.10M | $75.13M | $131.77M | $114.50M | $106.92M | $53.25M | $120.11M | $96.53M | $77.93M | $38.18M | $114.84M | $98.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 1.16% | 0.94% | 1.29% | 0.99% | 1.28% | 0.92% | 1.34% | 1.09% | 1.20% | 1.07% | 1.74% | 1.23% | 1.09% | 0.73% | 0.75% | 1.19% | 1.01% |
1 analysts predict BRKR's average Quarter EBITDA for Mar 24 to be $130.69M, with a high of $156.82M and a low of $104.55M. This is -9.81% lower than Bruker's previous annual EBITDA (Dec 23) of $144.90M.
Bruker Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 6 | 8 | 4 | 1 | 1 | 2 | 8 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $205.50M | $88.10M | $57.10M | $76.50M | $97.40M | $88.10M | $49.50M | $61.60M | $76.00M | $87.10M | $57.60M | $56.70M | $68.90M | $54.30M | $24.10M | $10.50M | $68.60M | $61.30M |
| Avg Forecast | $145.58M | $117.03M | $105.23M | $93.15M | $135.26M | $103.01M | $86.56M | $78.81M | $108.86M | $89.40M | $76.33M | $71.43M | $101.60M | $94.13M | $72.39M | $64.94M | $83.27M | $81.82M | $66.84M | $51.33M | $86.59M | $65.49M | $56.29M | $35.44M | $83.14M | $46.54M | $8.50M | $14.61M | $87.28M | $55.96M |
| High Forecast | $149.33M | $120.04M | $107.94M | $95.55M | $138.74M | $105.66M | $88.78M | $81.85M | $110.31M | $90.65M | $76.35M | $85.72M | $106.29M | $97.12M | $74.25M | $77.92M | $99.92M | $81.82M | $66.84M | $61.60M | $86.59M | $65.49M | $56.29M | $42.52M | $83.14M | $46.54M | $8.50M | $17.53M | $87.28M | $55.96M |
| Low Forecast | $142.46M | $114.51M | $102.97M | $91.15M | $132.35M | $100.80M | $84.70M | $77.30M | $105.95M | $88.14M | $76.31M | $57.14M | $96.91M | $92.64M | $70.83M | $51.95M | $66.62M | $81.82M | $66.84M | $41.07M | $86.59M | $65.49M | $56.29M | $28.35M | $83.14M | $46.54M | $8.50M | $11.69M | $87.28M | $55.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.02% | 0.94% | 0.79% | 1.18% | 1.17% | 1.08% | 0.74% | 1.20% | 0.88% | 1.33% | 1.02% | 1.60% | 0.83% | 1.17% | 2.83% | 0.72% | 0.79% | 1.10% |
Bruker's average Quarter net income forecast for Mar 24 is $71.43M, with a range of $57.14M to $85.72M. BRKR's average Quarter net income forecast represents a -65.24% decrease compared to the company's last Quarter net income of $205.50M (Dec 23).
Bruker SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 6 | 8 | 4 | 1 | 1 | 2 | 8 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $205.20M | $177.60M | $177.90M | $162.70M | $164.70M | $144.80M | $152.20M | $145.70M | $156.50M | $141.40M | $134.70M | $131.90M | $132.90M | $114.90M | $104.30M | $125.60M | $133.10M | $125.90M |
| Avg Forecast | $257.18M | $228.47M | $216.74M | $206.80M | $242.19M | $217.02M | $204.63M | $196.11M | $230.06M | $207.13M | $191.12M | $169.42M | $193.02M | $170.83M | $154.86M | $154.01M | $168.63M | $145.82M | $140.62M | $121.75M | $158.24M | $137.50M | $128.40M | $82.44M | $144.24M | $115.92M | $93.59M | $176.00M | $137.91M | $118.13M |
| High Forecast | $262.27M | $232.99M | $221.02M | $210.89M | $246.98M | $221.31M | $208.68M | $199.12M | $230.36M | $207.28M | $191.12M | $203.30M | $193.07M | $173.98M | $157.93M | $184.82M | $202.36M | $145.82M | $140.62M | $146.10M | $158.24M | $137.50M | $128.40M | $98.92M | $144.24M | $115.92M | $93.59M | $211.20M | $137.91M | $118.13M |
| Low Forecast | $252.93M | $224.69M | $213.15M | $203.38M | $238.19M | $213.43M | $201.25M | $193.68M | $229.77M | $206.98M | $191.12M | $135.53M | $192.97M | $168.22M | $152.31M | $123.21M | $134.90M | $145.82M | $140.62M | $97.40M | $158.24M | $137.50M | $128.40M | $65.95M | $144.24M | $115.92M | $93.59M | $140.80M | $137.91M | $118.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.15% | 1.06% | 0.98% | 0.99% | 1.08% | 1.20% | 0.99% | 1.03% | 1.05% | 1.60% | 0.92% | 0.99% | 1.11% | 0.71% | 0.97% | 1.07% |
Bruker's average Quarter SG&A projection for Mar 24 is $169.42M, based on 1 Wall Street analysts, with a range of $135.53M to $203.30M. The forecast indicates a -17.44% fall compared to BRKR last annual SG&A of $205.20M (Dec 23).
Bruker EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 6 | 8 | 4 | 1 | 1 | 2 | 8 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.41 | $0.60 | $0.39 | $0.52 | $0.66 | $0.60 | $0.33 | $0.41 | $0.50 | $0.58 | $0.38 | $0.37 | $0.45 | $0.35 | $0.16 | $0.07 | $0.45 | $0.40 |
| Avg Forecast | $0.98 | $0.79 | $0.71 | $0.63 | $0.91 | $0.69 | $0.58 | $0.53 | $0.73 | $0.60 | $0.51 | $0.47 | $0.68 | $0.63 | $0.49 | $0.55 | $0.72 | $0.55 | $0.45 | $0.42 | $0.59 | $0.44 | $0.38 | $0.33 | $0.56 | $0.31 | $0.06 | $0.23 | $0.59 | $0.38 |
| High Forecast | $1.00 | $0.81 | $0.73 | $0.64 | $0.93 | $0.71 | $0.60 | $0.55 | $0.74 | $0.61 | $0.51 | $0.47 | $0.71 | $0.65 | $0.50 | $0.56 | $0.74 | $0.55 | $0.45 | $0.42 | $0.59 | $0.44 | $0.38 | $0.33 | $0.56 | $0.31 | $0.06 | $0.23 | $0.59 | $0.38 |
| Low Forecast | $0.96 | $0.77 | $0.69 | $0.61 | $0.89 | $0.68 | $0.57 | $0.52 | $0.71 | $0.59 | $0.51 | $0.47 | $0.65 | $0.62 | $0.48 | $0.54 | $0.71 | $0.55 | $0.45 | $0.42 | $0.59 | $0.44 | $0.38 | $0.33 | $0.56 | $0.31 | $0.06 | $0.23 | $0.59 | $0.38 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.06% | 0.95% | 0.80% | 0.95% | 0.91% | 1.09% | 0.73% | 0.98% | 0.85% | 1.31% | 1.00% | 1.13% | 0.80% | 1.11% | 2.78% | 0.31% | 0.76% | 1.06% |
According to 1 Wall Street analysts, Bruker's projected average Quarter EPS for Mar 24 is $0.47, with a low estimate of $0.47 and a high estimate of $0.47. This represents a -67.01% decrease compared to BRKR previous annual EPS of $1.41 (Dec 23).
Bruker Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LUNG | Pulmonx | $6.13 | $13.00 | 112.07% | Buy |
| KIDS | OrthoPediatrics | $22.46 | $39.50 | 75.87% | Buy |
| LIVN | LivaNova | $49.94 | $68.25 | 36.66% | Buy |
| BRKR | Bruker | $57.81 | $79.00 | 36.65% | Buy |
| CNMD | CONMED | $71.23 | $97.00 | 36.18% | Buy |
| OFIX | Orthofix Medical | $17.93 | $24.00 | 33.85% | |
| IRTC | iRhythm | $91.45 | $111.38 | 21.79% | Buy |
| BIO | Bio-Rad Laboratories | $337.85 | $400.00 | 18.40% | Buy |
| ZBH | Zimmer Biomet | $108.06 | $121.78 | 12.70% | Hold |
| ITGR | Integer | $136.68 | $153.50 | 12.31% | Buy |
| FNA | Paragon 28 | $10.36 | $11.50 | 11.00% | Buy |
| AORT | Artivion | $28.90 | $30.75 | 6.40% | Buy |
| SRDX | Surmodics | $39.96 | $39.50 | -1.15% | Buy |
| GKOS | Glaukos | $146.35 | $144.14 | -1.51% | Buy |